• Industry experts share expertise, insight in next DealMaker webinar.
• Successful Reg A+ offerings tell their stories across multiple mediums.
• DealMaker is building a reputation for its ability to offer services that support companies across a wide array of needs.

With its mission of delivering speed, innovation and efficiency to global capital markets in mind, DealMaker has scheduled its next webinar. Slated for July 20, 2021, at 12 noon ET, the event will feature Don Yocham, executive director of the National Institute of Cannabis Investors, and Ryan Bradford, director of digital marketing at Creative Direct Marketing Group as well as DealMaker’s own Mike Werry, vice president of sales and marketing (https://ibn.fm/lpGbR). Savvy companies know that successful Reg A+ offerings tell their stories across multiple mediums, and DealMaker’s next webinar will delve into the details of what that means. Yocham and Bradford will share their expertise as they examine the way different channels can impact the success of an offering and provide insight to the various tools issuers have to bring their stories to the masses. Click here to register. DealMaker webinars (https://ibn.fm/ZtNnz) are designed to offer invaluable information across diverse but timely topics. The company is quickly building a reputation for its ability to offer a suite of services that support companies across a wide array of needs. DealMaker provides everything from an exclusive new-client onboarding platform that features a digital form that clients can complete and update with one click to its fund formation component that offers enhanced functionality for broker-dealer compliance teams and easy integration with fund management parts. The company also streamlines capital raise transactions, offering a proprietary subscription flow that has streamlined the path for tens of thousands of investors from all over the world to sign and fund — all online. The system’s real-time data optimizes deal flow for deal administrators and offers a variety of advanced payment solutions, making it easier than ever for investors to submit funds. Committed to offering its clients a simpler, cleaner way of doing things on one global platform, DealMaker has become the leading technology solution for companies looking to power their capital raises faster and more efficiently. Companies of all sizes, from startups to blue chip, use DealMaker to launch and market their offerings to investors across the globe. Since commencing operations in 2018, nearly 1,000 capital raises have been completed using DealMaker, including some of the most successful raises in the past three years. For more information about the company, visit www.DealMaker.tech. NOTE TO INVESTORS: The latest news and updates relating to DealMaker are available in the company’s newsroom at https://ibn.fm/Deal

• San Diego-based Tryp Therapeutics is developing new drug candidates with the aim of treating medical conditions that currently have limited effective therapy
• Tryp has solidified an agreement with the University of Michigan’s Chronic Pain & Fatigue Research Center and the Center for Consciousness Science to test synthetic psychedelic drug candidate TRP-8803 to advance its use in upcoming clinical trials
• The Company has also established an agreement with the University of Florida to test its lead drug candidate — TRP-8802 — for certain eating disorders
• Psychedelics are beginning to gain new respect and attention for addressing select neurological conditions as scientists, legislators and former drug opponents re-evaluate their views on the substances’ potential benefits

As a growing number of investigational scientists evaluate the potential of psychedelics to open a new field of medicinal solutions, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is moving forward with its mission to treat otherwise underserved chronic pain and eating disorder indications using its lead drug candidate TRP-8802, a synthetic psilocybin formulation. On July 7, the Company announced that an additional psilocybin-based formulation, TRP-8803, will be part of a series of upcoming bridging studies at the University of Michigan’s Chronic Pain & Fatigue Research Center and the Center for Consciousness Science in the Department of Anesthesiology. The aim of comparing TRP-8803 with conventional oral formulations of synthetic psilocybin in the studies is to “explore 1) the relationship between a psilocybin-induced increase in neurophysiological complexity and indices of pain in a preclinical model for chronic central pain, 2) the effect of alternative delivery methods of psilocybin on indices of pain and insular glutamate/GABA, and 3) PK analysis for blood samples from both oral and novel methods of delivery of psilocybin,” according to the announcement (https://ibn.fm/XL1B0). Tryp also entered an agreement with the University of Florida to conduct a Phase 2a clinical trial for treating certain eating disorders using TRP-8802, which is being forged in partnership with psychedelic therapy educational platform Fluence (https://ibn.fm/l3ERb) and Contract Research Organization (“CRO”) Clinlogix (https://ibn.fm/UGbSG). The TRP-8803 studies at the University of Michigan aim to similarly advance the drug candidate for neurological-based maladies toward future Phase 2b clinical trials. George Mashour, M.D., Ph.D., will advise the Company on its initial clinical study design for TRP-8803. Dr. Mashour is recognized globally as an expert on the neurobiology of consciousness and general anesthesia and he currently serves as the principal investigator for several NIH grants in the field of neuroscience, academic anesthesiology and translational science, according to the announcement. “I have been impressed with the scientific rigor and innovation from the team at Tryp as well as their collaborative spirit. I look forward to making great strides together toward addressing unmet patient needs in a wide range of indications,” Mashour stated. The University of Michigan has become a hotbed for medicinal psychedelics advocacy, and they believe society has reached a watershed moment for the substances’ acceptance for medical treatments. The Michigan Psychedelic Society was established in 2017 to promote education and harm reduction, and the U-M Student Association for Psychedelic Studies (“SAPS”) was launched the same year, building a steady increase in awareness (https://ibn.fm/nw2P1). The publishing wing of Harvard’s medical school likewise carried an article last month that noted, “Recently, psychedelic drugs have once again taken popular culture by storm. From the psychedelic startup companies newly forming on Wall Street to a recent New York Times article that claims ‘psychedelic drugs are closer to medicinal use ’ it seems that there is a renewed media and medical interest in acid (‘LSD’), mushrooms (psilocybin), ecstasy (‘MDMA’), ayahuasca, DMT (dimethyltryptamine), and ketamine” (https://ibn.fm/posm6). For more information on Tryp Therapeutics, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

• Drug delivery platform developer Lexaria Bioscience recently received its 20th patent — granted in Japan for beverages with lipophilic active agents
• The active agents include non-psychoactive cannabinoids and over-the-counter NSAIDS such as ibuprofen and aspirin that target pain and inflammation
• Lexaria’s DehydraTECH platform transforms drugs into a powder or liquid form that maintains the drug’s efficacy and allows it to be assimilated by the body more rapidly than normal oral ingestion of pills
• The company will also announce the latest results from six key R&D projects focusing on concentration levels, tolerability and avoidance of incidental new molecular entities (“NMEs”) soon

Drug assimilation technology innovator Lexaria Bioscience (NASDAQ: LEXX) is demonstrating the versatility of  its DehydraTECH platform with the announcement of a patent for “stable ready-to-drink beverage compositions comprising lipophilic active agents” — the company’s first granted in Japan. “This new patent adds to our existing suite of granted patents spanning the EU, the U.S., India and Australia, and continues to build value for Lexaria shareholders and clients,” CEO Chris Bunka stated (https://ibn.fm/hHDZf). The DehydraTECH technology converts drugs into a powder or liquid form that will make them orally ingestible at a level of quick absorption and efficacy that is competitive with smoked or vaporized drug use but without the risk of lung harm that may be a consequence of inhaling drugs. Processing drugs with DehydraTECH is being further evaluated through the company’s research and development program to establish that the drugs do not undergo unexpected changes in the process that would affect their safe use, and Lexaria expects to report its latest findings among six key R&D projects in the coming months (https://ibn.fm/ck0U3). The patent for beverage compositions with lipophilic active agents in Japan references active ingredients such as non-psychoactive cannabinoids and NSAIDS (ibuprofen, aspirin and similar OTC anti-inflammatory pain relievers). According to the announcement, Lexaria has 13 patent families among its worldwide patent applications. The Japan patent is the third one granted in its third family, and the 20th patent overall. Earlier this month, Lexaria announced its voluntary delisting of its common shares from the Canadian Securities Exchange (CSE ticker LXX) in order to focus its resources on the applied R&D programs, reduce fees and managerial requirements that came with a dual listing and to provide more liquidity for shareholders. “Since Lexaria’s shares began trading on the Nasdaq in January 2021, the overwhelming majority of trading has moved to Nasdaq,” the announcement states (https://ibn.fm/8kqL6). In animal studies, DehydraTECH-delivered drugs have been shown to reach the bloodstream in minutes instead of hours, thanks to molecular delivery through the lymphatic system instead of the digestive system and its “first pass” liver exposure. DehydraTECH thereby eliminates concerns about unwanted tastes and odors accompanying the medicines and increases bio-absorption of the partner drugs into blood circulation by 100 to 500 percent with even greater bio-absorption measured in brain tissue, which establishes the potential for advancing treatment of central nervous system disorders. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Scientific evidence is mounting that SARS-CoV-2 can cause neurological damage in patients hospitalized with the infection.
• A recent study that appeared in the journal JAMA Network Open finds five times increased mortality risk in patients hospitalized with COVID-19, citing encephalopathy as the most common neurological disease found in the clinical setting.
• As more research is needed to understand how COVID-19 affects the brain, Brain Scientific appears poised to offer technology solutions as a leading player in the neurological diagnostics space.

As the world learns more about the novel SARS-CoV-2 virus, the evidence about neurological symptoms developed by patients who suffered from COVID-19 is mounting, and the market for Brain Scientific’s (OTCQB: BRSF) innovative products appears to expand. A recent article published in Medical News Today discusses findings of the observational study examining neurological issues in patients hospitalized with COVID-19. The research which appeared in the journal JAMA Network Open unveils that the most prevalent neurological symptom observed in the clinical setting was acute encephalopathy also finding a relationship between neurological issues and a higher risk of dying in the hospital in patients infected with the SARS-CoV-2 virus (https://ibn.fm/j0F22). Although COVID-19 is considered a respiratory disease that mainly affects patients’ pulmonary systems, research is increasingly documenting that the disease can affect many other organs and systems, including the brain. Since the start of the pandemic, it has been observed in a clinical setting that some patients with COVID-19 have also developed neurological symptoms. However, more than a year into the pandemic, medical professionals and scientists alike still do not fully understand the prevalence of neurological problems or their relationship with mortality risk. To help fill this literature gap, Dr. Sherry Chou and her research team from the University of Pittsburgh School of Medicine performed an interim analysis of patient data collected from two large global consortia involving 3,744 patients across three cohorts. The study’s goal was to examine the incidence, type and outcomes of neurological manifestations among patients hospitalized with COVID-19. What data revealed was astonishing. The first cohort involving 3,055 patients hospitalized with COVID-19, both with and without neurological symptoms, unveiled that the most prevalent clinically reported neurological sign was acute encephalopathy, found in 50% of patients, while the most frequent self-reported symptom was headache (38%), and the loss of taste or smell (28%). The second and third cohorts involving patients with confirmed neurological issues and those who had received a neurological consultation also show encephalopathy as the most common neurological issue (53% and 24%, respectively). Again, it was followed by headaches and the loss of taste and smell as the most common self-reporting neurological symptoms. Research also reveals that if a patient has neurological issues resulting from COVID-19, it increases their risk of dying while in hospital by five times. Authors suggest that a formal neurological consultation may be needed in cases where doctors suspect neurological symptoms in individuals testing positive for COVID-19. Although an association between neurological issues in COVID-19 patients and an increased risk of in-hospital mortality has been established, more research is needed to identify if these neurological symptoms are causing the increase in mortality. Notwithstanding some practical limitations of the study, it lays the groundwork for future research involving standardized protocols, which may be able to track patients with neurological issues after they leave the hospital. As we learn more about the novel SARS-CoV-2 virus, it is becoming increasingly clear that neurological diagnostics will be at the center of the future post-COVID-19 health care of patients who suffered from the infection. Dr. Chou, the lead author of the study, emphasizes that even if we eradicate the pandemic, there are already millions of survivors who need neurological help, and there is still plenty of work in years to come. As a commercial-stage health care company focused on developing innovative medical devices and software disrupting the brain diagnostics market, Brain Scientific is poised to be at the center stage of neurological diagnostics space offering solutions for this growing public health problem with its two commercialized and FDA-cleared devices, NeuroCap(TM) and NeuroEEG(TM). Committed to a vision to allow medical professionals to conduct brain activity studies and collect diagnostic information more quickly, Brain Scientific appears well-positioned to offer solutions for the growing market need in the post-pandemic world. For more information, visit the company’s website at www.BrainScientific.com/Invest-Now. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• Experienced automotive industry veteran joins IMC as new president.
• Dubois has served as a leader at some of the most prestigious automotive organizations in the industry.
• New exec looking to build team that will lead Canadian operations to surpass even most optimistic projections.

DSG Global (OTCQB: DSGT) has announced that Christian Dubois, an auto executive with more than three decades of experience in the automotive industry, has accepted the role of president of Imperium Motors Canada, a division of DSGT’s Imperium Motor Corp. (“IMC”). IMC is an EV sales, manufacturing and marketing company that is gaining momentum and gathering attention for offering a variety of affordable electric vehicles equipped for the North American market. “Great companies are built on quality personnel, and we have exceeded any expectations,” said DSG Global CEO Robert Silzer. “Growth at times takes longer than planned; however, it’s obvious the hires of late are the best in the industry and will certainly assist in our corporate growth.” Dubois has served as a leader at some of the most prestigious automotive organizations in the industry. Most recently, he was regional director of operations and regional director of acquisitions and dealer development with the Dilawri Group of Companies, Canada’s largest automotive group. Dubois has also been with BMW Canada and Mercedes-Benz Canada. Dilawri employs more than 4,000 employees and has 76 franchised dealerships representing 35 automotive brands. And those aren’t the only numbers worth mentioning from Dubois’s stellar career. Thus far, he has managed 41 stores, worked with the executive teams of most OEMs, and represented dealers on multiple dealer councils. Retailers under his supervision have sold an estimated 80,000 cars and trucks, resulting in company revenues of more than $6 billion. He has been instrumental in acquiring 17 dealerships and in winning 13 open points; he has also won 11 Retailer of the Year awards. “Christian’s notoriety and experience in the automotive industry will allow Imperium to advance quickly toward becoming a top electric vehicle company,” said Imperium Motors president and CEO Rick Curtis. “He has strong plans for achieving strong sales rapidly, and his track record speaks for itself. Christian will be invaluable to our future success.” Dubois joins Imperium Motor Corp. as it focuses on making its mark in the U.S. EV space. The company is committed to offering EVs that feature a great design and a green mindset, as well as outstanding performance and functionality. IMC offerings will include high-speed, mid-speed and low-speed electric cars, trucks, SUVs, vans, buses and scooters. “Everyone by now has heard that the future is electric, and Imperium is about to introduce electric mobility in new segments and to new customers with affordable products that will redefine value,” said Dubois. “I am extremely excited to join Imperium and build the team that will lead our Canadian operations to surpass even the most optimistic projections.” DSG Global is an emerging global technology company with an array of interconnecting businesses in some of the fastest-growing market sectors. With roots in the golf industry, in which it specializes in fleet management with patented analytics, mobile touch-screen engagement and electric golf carts under the Vantage Tag Systems (“VTS”) brand, the company is moving quickly with road-ready electric vehicles for sale in the first quarter of 2021 through its Imperium Motor Company subsidiary. To learn more about the company, please visit www.DSGTGlobal.com. NOTE TO INVESTORS: The latest news and updates relating to DSGT are available in the company’s newsroom at https://ibn.fm/DSGT

• Clean Oceans campaign set to drive one of the largest ocean plastics cleanups in history.
• Campaign offers participants weekly prizes and one $50,000 grand prize.
• Powered by Lottery.com, WinTogether.org innovates the way charitable organizations raise funds and interact with donors.

WinTogether.org, a charitable sweepstakes platform powered by Lottery.com, has launched the Clean Oceans campaign to support Ocean Voyages Institute (“OVI”), whose goal is to remove one million pounds of plastics and ghost nets from the Great Pacific Garbage Patch (https://ibn.fm/5QM2c) “The teams at WinTogther.org and OVI are excited to announce the launch of the Clean Oceans campaign,” said Lottery.com CEO Tony DiMatteo. “We hope that our joint effort helps the public rally around this important issue and drives one of the largest cleanups of ocean plastics and ghost nets in history.” The Clean Oceans campaign, which launched in June and will run through Aug. 31, 2021, offers weekly prizes to participants as well as a $50,000 grand prize, sponsored by Lottery.com. Participants become eligible for those prizes by donating at https://wintogether.org. This campaign is the first time WinTogether.org has partnered with Causes.com and Countable, which serve major brands and nonprofits, including Tesla, Patagonia Inc. and Red Nose Day. WinTogether.org is also working on this campaign with Dollar Donation Club, whose pre-campaign work with OVI was central to the activation of the campaign. WinTogether.org is a charitable sweepstakes platform focused on building the future of philanthropy. Founded and operated by Lottery.com, WinTogether.org has innovated the way charitable organizations raise funds and interact with donors by gamifying charitable giving. As part of its fundraising efforts, WinTogether.org incentivizes donors to get involved by offering the opportunity to win cash prizes, once-in-a-lifetime experiences, and luxury prizes. WinTogether.org is aligned with the United Nations 17 Sustainable Development Goals and works with some of the largest nonprofits in the world to provide a new channel to raise awareness and funds, as well as provide opportunities for donors around the world to support worthwhile causes. A portion of the donations are received by the WinTogether Trust, a registered 501(c)(3) organization, which donates directly to the named campaign. AutoLotto Inc., doing business as Lottery.com, is a leading technology company that is transforming how, where and when lottery is played. Its engaging mobile and online platforms enable players and commercial partners located in the United States and internationally to remotely purchase legally sanctioned lottery games. Fans and subscribers look to Lottery.com for compelling, real-time results on more than 800 lottery games from more than 40 countries. Additionally, through WinTogether.org, Lottery.com is fundamentally changing how nonprofit donors are incentivized to action by gamifying charitable giving. In all that it does, Lottery.com’s mission remains the same: an uncompromising passion to innovate, grow a new demographic of enthusiasts, deliver responsible and trusted solutions, and promote community and philanthropic initiatives. On Feb. 22, 2021, the company entered into a definitive agreement with Trident Acquisitions Corp. (NASDAQ: TDAC) to become a publicly traded company. For more information, visit the company’s website at www.Lottery.com. NOTE TO INVESTORS: The latest news and updates relating to Lottery.com are available in the company’s newsroom at https://ibn.fm/Lottery Important Notice Regarding Forward-Looking Statements This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements, other than statements of present or historical fact included in this presentation, regarding the proposed business combination, Trident and Lottery.com’s ability to consummate the proposed business combination, the benefits of the transactions and the combined company’s future financial performance, as well as the combined company’s strategy, future operations, estimated financial position, estimated revenues and losses, projected costs, prospects, plans and objectives of management are forward-looking statements. When used in this press release, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. Except as otherwise required by applicable law, Trident and Lottery.com disclaim any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this Current Report. Trident and Lottery.com caution you that these forward-looking statements are subject to numerous risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of either Trident or Lottery.com. In addition, Trident cautions you that the forward-looking statements contained in this press release are subject to the following factors: (i) the occurrence of any event, change or other circumstances that could delay the business combination or give rise to the termination of the agreements related thereto; (ii) the outcome of any legal proceedings that may be instituted against Trident or Lottery.com following announcement of the transactions; (iii) the inability to complete the business combination due to the failure to obtain approval of the shareholders of Trident, or other conditions to closing in the merger agreement; (iv) the risk that the proposed business combination disrupts Lottery.com’s current plans and operations as a result of the announcement of the transactions; (v) Lottery.com’s ability to realize the anticipated benefits of the business combination, which may be affected by, among other things, competition and the ability of Lottery.com to grow and manage growth profitably following the business combination; (vi) costs related to the business combination; (vii) risks related to the rollout of Lottery.com’s business and the timing of expected business milestones; (viii) Lottery.com’s dependence on obtaining and maintaining lottery retail licenses or consummating partnership agreements in various markets; (ix) Lottery.com’s ability to maintain effective internal controls over financial reporting, including the remediation of identified material weaknesses in internal control over financial reporting relating to segregation of duties with respect to, and access controls to, its financial record keeping system, and Lottery.com’s accounting staffing levels; (x) the effects of competition on Lottery.com’s future business; (xi) risks related to Lottery.com’s dependence on its intellectual property and the risk that Lottery.com’s technology could have undetected defects or errors; (xii) changes in applicable laws or regulations; (xiii) the COVID-19 pandemic and its effect directly on Lottery.com and the economy generally; (xiv) risks related to disruption of management time from ongoing business operations due to the proposed business combination; (xv) risks relating to privacy and data protection laws, privacy or data breaches, or the loss of data; (xvi) the possibility that Lottery.com may be adversely affected by other economic, business, and/or competitive factors; (xvii) the ability of the campaign to raise sufficient funds to remove its stated goal of 1 million pounds of plastics and ghost nets from the ocean, or at all. Should one or more of the risks or uncertainties described in this Current Report materialize or should underlying assumptions prove incorrect, actual results and plans could differ materially from those expressed in any forward-looking statements. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that Trident has filed and will file from time to time with the SEC, including its Annual Report on Form 10-K/A for the fiscal year ended December 31, 2020. Trident’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Important Information and Where to Find it The proposed business combination will be submitted to shareholders of Trident for their consideration. Trident has filed a Registration Statement on Form S-4 with the SEC which includes a preliminary proxy statement and will include a definitive proxy statement to be distributed to Trident’s stockholders in connection with Trident’s solicitation for proxies for the vote by Trident’s stockholders in connection with the proposed business combination and other matters as described in the Registration Statement, as well as the prospectus relating to the offer of the securities to be issued to Lottery.com’s shareholders in connection with the completion of the proposed business combination. After the Registration Statement has been declared effective, Trident will mail a definitive proxy statement and other relevant documents to its shareholders as of the record date established for voting on the proposed business combination. Trident’s shareholders and other interested persons are advised to read the preliminary proxy statement / prospectus and any amendments thereto and, once available, the definitive proxy statement / prospectus, in connection with Trident’s solicitation of proxies for its special meeting of shareholders to be held to approve, among other things, the proposed business combination, because these documents will contain important information about Trident, Lottery.com and the proposed business combination. Stockholders may also obtain a copy of the preliminary proxy statement or, once available, the definitive proxy statement, as well as other documents filed with the SEC regarding the proposed business combination and other documents filed with the SEC by Trident, without charge, at the SEC’s website located at www.sec.gov or by directing a request to Cody Slach, (949) 574-3860, TDAC@gatewayir.com. The information contained on, or that may be accessed through, the websites referenced in this press release is not incorporated by reference into, and is not a part of, this press release. Participants in the Solicitation Trident and its directors and officers may be deemed participants in the solicitation of proxies of Trident’s stockholders in connection with the proposed business combination. Lottery.com and its officers and directors may also be deemed participants in such solicitation. Security holders may obtain more detailed information regarding the names, affiliations and interests of certain of Trident’s executive officers and directors in the solicitation by reading Trident’s Annual Report on Form 10-K/A for the fiscal year ended December 31, 2020, and the Registration Statement and other relevant materials filed with the SEC in connection with the business combination when they become available. Information concerning the interests of Trident’s participants in the solicitation, which may, in some cases, be different than those of their stockholders generally, will be set forth in the proxy statement relating to the business combination when it becomes available. No Offer or Solicitation This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.

Date: JULY 22-23, 2021 ONLINE LIVESTREAM Chief Patient officers and leaders of engagement, advocacy, communications and support services, are invited to attend the inaugural Chief Patient Officer Summit on July 22-23, 2021, organized by DGE. This online live-streaming event is driven to focus on opportunities and challenges faced by Chief Patient officers and executives while offering a seamless patient experience. The event is hosted by Dynamic Global Events (“DGE”), a life science leader in organizing b2b events. The global event company caters to the dynamic informational and networking needs of the pharmaceutical, biotechnology, healthcare, medical devices, and allied industries. The CPO summit will offer a viable platform for professionals to join hands in identifying patient needs with meticulous research and analysis. It will also offer better diversity and inclusion in clinical trials as well as affordable access and patient support. This 2-day online live-streaming event provides insights into the concerning issues and solutions for smooth execution. The online event will be graced by the presence of eminent industry thinkers and speakers who will share their expert opinion and insights into effective ideas for working compliantly with patients and patient advocacy organizations. The CPO Summit Agenda: The 2-day event will cover discussions on fostering internal cross-functional partnerships with clinical operations and regulatory teams to bring the patient voice into clinical trial design. This summit will be a learning platform to understand the strategic global approaches for working with advocates in various health care systems around the globe. Participants can connect with peers and avail tips and valuable advice on how to make patient centricity part of their organization’s HR onboarding process. Discussions will include developing the best methods in advocacy and engagement roles pre and post clinical at small, mid and large companies. Executives will also discuss the impact of the pandemic, new and effective ideas in the digital scenario, and global strategies for harmonious communication among healthcare systems across the world. The main focus of the event is to ensure the growth of patient officers and successful communication across the medical spectrum for an enhanced patient experience. To know more about the event, please visit https://ibn.fm/fcnes.

• Cannabis sales in California hit $4.4 billion last year, up 57% from the year prior.
• Consumers are relying on home delivery for many goods, including cannabis.
• With its Nug Avenue acquisition, SGMD plans to make significant impact on LA cannabis delivery marketplace.

Boasting the largest state economy in the country and the sixth largest economy in the world, California also tops the global marijuana market, with a Forbes article reporting that cannabis sales in the state hit$4.4 billion last year, up 57% from the year prior (https://ibn.fm/Dj8Rl). With much of that growth driven by increased use of delivery services as consumers are increasingly relying on home delivery for many goods, including cannabis, Sugarmade Inc. (OTC: SGMD) is leveraging its position as a 70% stakeholder in NUG Avenue, a cannabis delivery service based in Southern California. Cannabis delivery is key to California’s cannabis growth, according to the Forbes article, which noted that “interesting findings from the report include the massive influx in delivery sales, as well as consumers who used delivery for the first time this year. The peak for first-time delivery users was March and April 2020, coinciding with lockdowns. Many cannabis industry operators saw the most consistent April sales ever. Eaze reports a 59% increase in new customer sign-ups, a 44% increase in first-time deliveries and a 15% increase in order volume.” Those numbers come as no surprise to Sugarmade, an innovator in the dynamic California cannabis scene that has made a significant investment in the cannabis-delivery space. Earlier this year, SGMD announced its Nug acquisition, along with unveiling a new business initiative for the licensed delivery of cannabis products to consumers in the Los Angeles metropolitan area (https://ibn.fm/2iQUN). “We strongly believe the LA delivery market is the prime spot for expansion of our business,” said Sugarmade CEO Jimmy Chan. “California is the world’s sixth-largest economy, and LA County is by far the most significant driver, with over 25% of the state’s population. The Lynwood, California, site is optimal, as it is located along one of the major distribution freeways, allowing drivers to efficiently reach the more than 15 million consumers that live within a 30-mile radius of the new location. We plan to make a big impact on the LA cannabis delivery marketplace.” Sugarmade’s acquisition agreement, which outlines a 70% stake in the Lynwood, California, operations of Nug Avenue, a California corporation, also indicates the company will recognize 70% of the revenues and profits from Nug Avenue’s Lynwood delivery service operations. In addition, the agreement gives SGMD first rights of refusal on all future investments into Nug Avenue and an option on all future business operations, including expansion into additional delivery areas. Sugarmade Inc. is a product and branding marketing company investing in operations and technologies with disruptive potential. In addition to its financial interest in the BudCars brand, SGMD’s brand portfolio includes NUG Avenue, CarryOutsupplies.com and SugarRush(TM). To learn more about Sugarmade, please visit www.sugarmade.com. NOTE TO INVESTORS: The latest news and updates relating to SGMD are available in the company’s newsroom at http://ibn.fm/SGMD

• Singapore-based fandom fintech firm BAND Royalty has introduced its revolutionary music NFTs that include a royalty revenue-sharing platform
• The NFTs’ art DeFi utility features royalties from select songs by popular artists including Cher, Beyonce, will.i.am and Justin Timberlake
• The NFTs are produced as “albums” of differing degrees of rarity and staking power
• Art NFTs, including those anchored to the music industry, have been growing in popularity in recent years and BAND is the first company to establish its own music-only NFT trading marketplace

By now the cat is well out of the bag that non-fungible tokens (“NFTs”) are trending with a growing role in the music industry, catering to fans’ desires to hold collectibles representing their favorite artists but also to fans’ hopes of turning a little profit on the collectibles trading scene (https://ibn.fm/v9p7B). The rise of music NFTs follows on the heels of low-tech vinyl recordings’ resurgence over the past 15 years, accelerated to overdrive during the past year’s pandemic conditions as an apparent result of fans’ desires for art that transcends the listening experience — especially in the absence of concert events. A report by VICE noted that the vinyl market grew 28.7% in 2020, outperforming CDs in revenues for the first time since the 1980s and stressing the supply chain (https://ibn.fm/LCA0Y). Singapore-based BAND Royalty is disrupting the music industry revenue stream as the first creator of a music-only NFT marketplace tied to the royalties from leading artists. The NFTs will soon be tokenized to allow even more people to get involved. BAND Royalty issued its first series of 3,000 NFTs in May, beginning with a private pre-sale and then open public access to the remaining NFT “albums.” BAND’s NFT marketplace can be found on its website, where three additional series of NFT albums will also appear during the coming year, each with 3,000 new NFTs of varying rarity and staking power to comprise 12,000 BAND NFTs in total once the rollout is completed. The NFTs can be staked in royalty pools established by the company, meaning they are secured to the platform without the option of being traded elsewhere for a specified period of time. The pools include the opportunity for stakeholders to share a percentage of the royalty revenues derived from select pieces of music as they are either performed mechanically or publicly, sold in printed form or synchronized with visual media such as film, advertisements and video games. BAND has purchased these royalty rights for selections by artists including Cher, Beyonce, will.i.am and Justin Timberlake for the current series. The NFTs feature digital works of art that may enhance their value as collectibles that can be traded or sold to other fans. “What we’re doing with non-fungible tokens is so off the charts that no one has seen it before,” BAND co-founder Noble Drakoln said during a live-streamed raffle of one of the NFT “albums” May 27 (https://ibn.fm/l4FZQ). “What we decided to do is to make a full-blown eco-system. The NFTs are the base of system. … We really wanted to make sure that we had from day one a global enterprise that was already crypto accessible. Because as we expand in this ecosystem our goal is just to make the process of collecting music royalties a lot more transparent for the artists and to get them to their fans a lot faster.” For more information on BAND Royalty, visit the company’s website at www.BandRoyalty.com. NOTE TO INVESTORS: The latest news and updates relating to BAND are available in the company’s newsroom at https://ibn.fm/BAND

• Most recently SGMD signed MOU to obtain three non-storefront California cannabis licenses.
• Sugarmade plans to open three new Nug Avenue cannabis delivery hubs in the Los Angeles metro area.
• In May, the company completed the acquisition of Lemon Glow Company Inc., along with all of its assets, interests, property and rights.

In a series of strategic acquisitions, Sugarmade Inc. (OTC: SGMD) has strengthened its position as a growing presence in the California cannabis sector. The company, which is currently a central player in the state’s expanding cannabis delivery space, is focused on developing a full farm-to-door vertically integrated cannabis business. In the company’s most recent move, Sugarmade signed a memorandum of understanding to obtain three non-storefront California cannabis licenses from the Los Angeles Department of Cannabis Regulation, along with corresponding licenses from the California Bureau of Cannabis Control (https://ibn.fm/U63Am). Combined, the licenses provide the foundation for the opening of three new Nug Avenue cannabis delivery hubs in the Los Angeles metro area; Sugarmade currently owns a 70% stake in NUG Avenue, a cannabis delivery service based in southern California that offers hand-selected, top-shelf cannabis products. “Our first Nug Avenue location has been a tremendous success, but we need to expand due to overwhelming demand,” said Sugarmade CEO Jimmy Chan. “Holding these licenses will provide an optimal solution to our current growth limitations. By using these licenses to cover manufacturing, distribution and delivery, we hope to further develop our fully vertical approach to the dynamic California cannabis delivery market. With this agreement, we gain the potential to manufacture and package our own cannabis products, distribute them to multiple Nug Avenue locations, and then deliver them right to the front door of our loyal customer base, driving both top-line and bottom-line growth potential as we expand our footprint in this rapidly growing space.” Just a month earlier, in May, Sugarmade completed the acquisition of Lemon Glow Company Inc., along with all of its assets, interests, property and rights; a key piece of the acquisition included 640 acres of Lake County real estate located outside of the commercial cannabis cultivation exclusion zones (https://ibn.fm/kQ4Sg). According to the company, 32 acres of the property have already been designated for outdoor cannabis cultivation, and the annual potential cultivation yield at the property is estimated to be approximately 4,000 pounds of dry trimmed cannabis flower per acre per year, which represents approximately 128,000 pounds, or 64 tons, of dry trimmed cannabis flower per year in total. “This step brings us closer to closing the loop on what we believe to be one of the most promising vertically integrated cannabis models in the thriving California market,” said Chan. “We are setting the stage to improve margins while expanding end-market access, and to grow, refine, produce, distribute, sell, and home-deliver top cannabis products in the largest and fastest growing cannabis market on the planet. This acquisition positions us to achieve that objective with a significant capacity to scale as demand for our products and services grows over time.” Sugarmade Inc. is a product and branding marketing company investing in operations and technologies with disruptive potential. In addition to its financial interest in the BudCars brand, SGMD’s brand portfolio includes NUG Avenue, CarryOutsupplies.com and SugarRush(TM). To learn more about Sugarmade, please visit www.sugarmade.com. NOTE TO INVESTORS: The latest news and updates relating to SGMD are available in the company’s newsroom at http://ibn.fm/SGMD